Next-gen COVID-19 Vaccine
COVID-19
Key Facts
About United Immunity
A Japanese biotech developing DC-SIGN-targeting nanoparticle platforms for myeloid cell-specific drug delivery in oncology and immunology.
View full company profileAbout Novavax
Novavax is a mission-driven biotech focused on discovering, developing, and commercializing innovative protein-based vaccines to address serious infectious diseases. Its core achievement is the successful global commercialization of Nuvaxovid®, a COVID-19 vaccine, validating its integrated technology platform of recombinant nanoparticle antigens and the Matrix-M adjuvant. The company's strategy centers on advancing a high-value pipeline in influenza and other infectious diseases while pursuing strategic partnerships and exploring new applications for its adjuvant technology in areas like oncology to drive long-term growth.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |